GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Current Ratio

Perspective Therapeutics (Perspective Therapeutics) Current Ratio : 1.07 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Perspective Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 1.07.

Perspective Therapeutics has a current ratio of 1.07. It generally indicates good short-term financial strength.

The historical rank and industry rank for Perspective Therapeutics's Current Ratio or its related term are showing as below:

CATX' s Current Ratio Range Over the Past 10 Years
Min: 1.07   Med: 10.88   Max: 37.37
Current: 1.07

During the past 13 years, Perspective Therapeutics's highest Current Ratio was 37.37. The lowest was 1.07. And the median was 10.88.

CATX's Current Ratio is ranked worse than
87.53% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: 2.73 vs CATX: 1.07

Perspective Therapeutics Current Ratio Historical Data

The historical data trend for Perspective Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Current Ratio Chart

Perspective Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.53 3.50 37.37 26.18 1.07

Perspective Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.46 5.60 3.72 2.67 1.07

Competitive Comparison of Perspective Therapeutics's Current Ratio

For the Medical Devices subindustry, Perspective Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Current Ratio falls into.



Perspective Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Perspective Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=16.837/15.664
=1.07

Perspective Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=16.837/15.664
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perspective Therapeutics  (AMEX:CATX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Perspective Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics (Perspective Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Hills Street, Suite 106, Richland, WA, USA, 99354
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.
Executives
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354